Quick Answer
Acrivon Therapeutics, Inc. reported Net Income of -$77.91 million for fiscal year 2025.
Acrivon Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$77.91M | +3.3% |
| 2024 | -$80.56M | -33.4% |
| 2023 | -$60.39M | -93.8% |
| 2022 | -$31.17M | -91.9% |
| 2021 | -$16.24M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$18.23M | +18.7% | +13.2% |
| June 30, 2025 | -$21.01M | -11.7% | -6.7% |
| March 31, 2025 | -$19.68M | -19.4% | +12.3% |
| September 30, 2024 | -$22.44M | -55.1% | -19.4% |
| June 30, 2024 | -$18.80M | -35.1% | -14.0% |
| March 31, 2024 | -$16.49M | -29.2% | -14.0% |
| September 30, 2023 | -$14.47M | -57.3% | -4.0% |
| June 30, 2023 | -$13.91M | -139.1% | -9.1% |
- Acrivon Therapeutics, Inc. showed an increase of +3.3% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s net income has declined by 379.6% (from -$16.24 million to -$77.91 million).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: